albuterol (Ventolin) vs fluticasone furoate/umeclidinium/vilanterol

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Asthma

Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline

albuterol (Ventolin)

Marketed by GlaxoSmithKline

Approved in Asthmasmall molecule
Weak signal

NCT00144846 · Phase 3 · completed

Although the registry describes 80 participants as randomized and double-blind, it lists only a single albuterol arm with no placebo or active comparator. The primary endpoint was safety, and no results are posted, so the study cannot provide a controlled comparison of treatment benefit.

Next expected readout: April 2027 · NCT06433921 (registry estimate)

No aligned efficacy figure on record for this race.

fluticasone furoate/umeclidinium/vilanterol · Trelegy Ellipta

Marketed by GlaxoSmithKline

Approved in Asthmasmall molecule combination
Reliable signal

NCT02924688 · Phase 3 · completed

This was a large (N=2,436) randomized, triple-blind, active-controlled Phase III trial comparing four fixed-dose combinations of fluticasone furoate/umeclidinium/vilanterol against two fluticasone furoate/vilanterol dual therapy controls in patients with inadequately controlled asthma. The primary endpoint, change from baseline in trough FEV1 at Week 24, was met for every pre-specified triple-therapy versus dual-therapy comparison, with all four least-squares mean differences favoring triple therapy and p<0.001. The combination of randomization, blinding, an active comparator, a large sample, a hard clinical endpoint, and a statistically significant primary result constitutes strong evidence.

Next expected readout: January 2027 · NCT05757102 (registry estimate)

Reported efficacy

Mean Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 24 (Baseline (pre-dose at Day 1) and Week 24): Week 24 trough FEV1: FF/UMEC/VI vs FF/VI treatment differences 0.096 L (95% CI 0.052 to 0.139; p<0.001), 0.110 L (95% CI 0.066 to 0.153; p<0.001), 0.082 L (95% CI 0.039 to 0.125; p<0.001), and 0.092 L (95% CI 0.049 to 0.135; p<0.001). (met)

Result source: NCT02924688

Results for Asthma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointalbuterol (Ventolin)fluticasone furoate/​umeclidinium/​vilanterol
Severe exacerbations, annualised rate—Not posted · NCT06657066—Trial running · NCT04651777
Trough FEV1, change0.1 vs 0.0vs ADVAIR DISKUS200 mcg · wk 26 · n 120NCT02175771
14 other results
  • 0.1 vs 0.0 200/12.5 mcg · wk 26 · n 130 · Phase 3 · secondary NCT02175771
  • 0.1 vs 0.0 100 mcg · wk 26 · n 123 · Phase 3 · secondary NCT02175771
  • 0.1 vs 0.0 100/12.5 mcg · wk 26 · n 119 · Phase 3 · secondary NCT02175771
  • 0.3 vs 0.1 100 mcg · wk 12 · n 94 · Phase 2 · primary NCT01479621
  • 0.2 vs 0.1 50 mcg · wk 12 · n 100 · Phase 2 · primary NCT01479621
  • 0.1 vs 0.0 250 µg QD · wk 2 · n 117 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 125 µg QD · wk 2 · n 113 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 62.5 µg QD · wk 2 · n 122 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 31.25 µg QD · wk 2 · n 124 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 31.25 µg BID · wk 2 · n 118 · Phase 2 · primary NCT01641692
  • 0.2 vs 0.1 25 mcg · wk 12 · n 97 · Phase 2 · primary NCT01479621
  • 0.1 vs 0.0 15.6 µg QD · wk 2 · n 120 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 15.6 µg BID · wk 2 · n 113 · Phase 2 · primary NCT01641692
  • 0.2 vs 0.1 12.5 mcg · wk 12 · n 94 · Phase 2 · primary NCT01479621
0.1 vs 0.1vs FF/VI100/31.25/25 mcg · wk 24 · n 399NCT02924688
5 other results
  • 0.2 vs 0.1 200/31.25/25 mcg · wk 24 · n 399 · Phase 3 · primary NCT02924688
  • 0.1 vs 0.1 100/62.5/25 mcg · wk 24 · n 404 · Phase 3 · primary NCT02924688
  • 0.2 vs 0.1 200/62.5/25 mcg · wk 24 · n 405 · Phase 3 · primary NCT02924688
  • 0.1 vs 0.1 FF 100 ug, UMEC 62.5 ug, VI 25 ug · wk 12 · n 87 · Phase 3 · primary NCT04937387
  • 0.1 vs 0.1 FF 200 ug, UMEC 62.5 ug, VI 25 ug · wk 12 · n 82 · Phase 3 · secondary NCT04937387
ACQ-5, change—Not posted · NCT06657066—Trial running · NCT04651777
OCS dose reduction—Not posted · NCT06657066—Trial running · NCT04651777

Severe exacerbations, annualised rate

albuterol (Ventolin)
—Not posted · NCT06657066
fluticasone furoate/​umeclidinium/​vilanterol
—Trial running · NCT04651777

Trough FEV1, change

albuterol (Ventolin)
0.1 vs 0.0vs ADVAIR DISKUS200 mcg · wk 26 · n 120NCT02175771
14 other results
  • 0.1 vs 0.0 200/12.5 mcg · wk 26 · n 130 · Phase 3 · secondary NCT02175771
  • 0.1 vs 0.0 100 mcg · wk 26 · n 123 · Phase 3 · secondary NCT02175771
  • 0.1 vs 0.0 100/12.5 mcg · wk 26 · n 119 · Phase 3 · secondary NCT02175771
  • 0.3 vs 0.1 100 mcg · wk 12 · n 94 · Phase 2 · primary NCT01479621
  • 0.2 vs 0.1 50 mcg · wk 12 · n 100 · Phase 2 · primary NCT01479621
  • 0.1 vs 0.0 250 µg QD · wk 2 · n 117 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 125 µg QD · wk 2 · n 113 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 62.5 µg QD · wk 2 · n 122 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 31.25 µg QD · wk 2 · n 124 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 31.25 µg BID · wk 2 · n 118 · Phase 2 · primary NCT01641692
  • 0.2 vs 0.1 25 mcg · wk 12 · n 97 · Phase 2 · primary NCT01479621
  • 0.1 vs 0.0 15.6 µg QD · wk 2 · n 120 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 15.6 µg BID · wk 2 · n 113 · Phase 2 · primary NCT01641692
  • 0.2 vs 0.1 12.5 mcg · wk 12 · n 94 · Phase 2 · primary NCT01479621
fluticasone furoate/​umeclidinium/​vilanterol
0.1 vs 0.1vs FF/VI100/31.25/25 mcg · wk 24 · n 399NCT02924688
5 other results
  • 0.2 vs 0.1 200/31.25/25 mcg · wk 24 · n 399 · Phase 3 · primary NCT02924688
  • 0.1 vs 0.1 100/62.5/25 mcg · wk 24 · n 404 · Phase 3 · primary NCT02924688
  • 0.2 vs 0.1 200/62.5/25 mcg · wk 24 · n 405 · Phase 3 · primary NCT02924688
  • 0.1 vs 0.1 FF 100 ug, UMEC 62.5 ug, VI 25 ug · wk 12 · n 87 · Phase 3 · primary NCT04937387
  • 0.1 vs 0.1 FF 200 ug, UMEC 62.5 ug, VI 25 ug · wk 12 · n 82 · Phase 3 · secondary NCT04937387

ACQ-5, change

albuterol (Ventolin)
—Not posted · NCT06657066
fluticasone furoate/​umeclidinium/​vilanterol
—Trial running · NCT04651777

OCS dose reduction

albuterol (Ventolin)
—Not posted · NCT06657066
fluticasone furoate/​umeclidinium/​vilanterol
—Trial running · NCT04651777
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. albuterol (Ventolin): 4 of 4 rows · fluticasone furoate/umeclidinium/vilanterol: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricalbuterol (Ventolin)fluticasone furoate/​umeclidinium/​vilanterol
Dropout rate
10%100 mg SCa
NCT04276233 · Phase 4 · registry result, not featured evidence
show 38 more results
—Exercising in Filtered Air Followi
NCT05087693 · Phase 4 · registry result, not featured evidence
—Exercising in Ozone Following Salb
NCT05087693 · Phase 4 · registry result, not featured evidence
16.7%
NCT03924635 · Phase 4 · registry result, not featured evidence · combination
4.8%100 mg SC
NCT02654145 · Phase 4 · registry result, not featured evidence
—
NCT01471340 · Phase 4 · registry result, not featured evidence · pooled
7.7%50/250 mcg
NCT00363480 · Phase 4 · registry result, not featured evidence
2.1%100/62.5/25 mcg
NCT03184987 · Phase 3 · registry result, not featured evidence
11.1%100/62.5/25 mcg to 200/62.5/25 mcg
NCT03184987 · Phase 3 · registry result, not featured evidence
7.3%200/62.5/25 mcg
NCT03184987 · Phase 3 · registry result, not featured evidence
2.2%100/10 mcg BID
NCT02741271 · Phase 3 · registry result, not featured evidence
—
NCT02502734 · Phase 3 · registry result, not featured evidence
—200/12.5 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
—200 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
—100/12.5 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
—100 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
5.7%
NCT01687296 · Phase 3 · registry result, not featured evidence
12.6%200 µg OD
NCT01431950 · Phase 3 · registry result, not featured evidence
16%100 µg OD
NCT01431950 · Phase 3 · registry result, not featured evidence
18.5%160 µg
NCT00384189 · Phase 3 · registry result, not featured evidence
18.3%80 µg
NCT00384189 · Phase 3 · registry result, not featured evidence
16.4%40 µg
NCT00384189 · Phase 3 · registry result, not featured evidence
—800 μg
NCT02479412 · Phase 2 · registry result, not featured evidence
—250 μg
NCT02479412 · Phase 2 · registry result, not featured evidence
—58 μg
NCT02479412 · Phase 2 · registry result, not featured evidence
—100 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
—50 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
—25 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
—12.5 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
5.1%250 µg QD
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
9.3%125 µg QD
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
0%62.5 µg QD
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
—31.5 µg QD
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
5.9%31.25 µg BID
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
2%31.25 µg QD
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
0%15.6 µg BID
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
0%15.6 µg QD
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
—200 ug
NCT06433908 · Phase 1 · registry result, not featured evidence
—800 ug
NCT06433908 · Phase 1 · registry result, not featured evidence
7.7%100/31.25/25 mcgb
NCT02924688 · Phase 3 · combination · Asthma · phase 3
show 8 more results
5.7%200/31.25/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
5.7%100/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
5.9%200/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
3.4%FF 200 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3
0%FF 100 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3
2.1%100/62.5/25 mcg
NCT03184987 · Phase 3 · combination
11.1%100/62.5/25 mcg to 200/62.5/25 mcg
NCT03184987 · Phase 3 · combination
7.3%200/62.5/25 mcg
NCT03184987 · Phase 3 · combination
Discontinued due to AEs
1%100 mg SCa
NCT04276233 · Phase 4 · registry result, not featured evidence
show 38 more results
—Exercising in Filtered Air Followi
NCT05087693 · Phase 4 · registry result, not featured evidence
—Exercising in Ozone Following Salb
NCT05087693 · Phase 4 · registry result, not featured evidence
—
NCT03924635 · Phase 4 · registry result, not featured evidence · combination
—100 mg SC
NCT02654145 · Phase 4 · registry result, not featured evidence
—
NCT01471340 · Phase 4 · registry result, not featured evidence · pooled
1.8%50/250 mcg
NCT00363480 · Phase 4 · registry result, not featured evidence
2.1%100/62.5/25 mcg
NCT03184987 · Phase 3 · registry result, not featured evidence
0%100/62.5/25 mcg to 200/62.5/25 mcg
NCT03184987 · Phase 3 · registry result, not featured evidence
1.8%200/62.5/25 mcg
NCT03184987 · Phase 3 · registry result, not featured evidence
—100/10 mcg BID
NCT02741271 · Phase 3 · registry result, not featured evidence
—
NCT02502734 · Phase 3 · registry result, not featured evidence
—200/12.5 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
—200 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
—100/12.5 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
—100 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
—
NCT01687296 · Phase 3 · registry result, not featured evidence
1.7%200 µg OD
NCT01431950 · Phase 3 · registry result, not featured evidence
1.7%100 µg OD
NCT01431950 · Phase 3 · registry result, not featured evidence
—160 µg
NCT00384189 · Phase 3 · registry result, not featured evidence
—80 µg
NCT00384189 · Phase 3 · registry result, not featured evidence
—40 µg
NCT00384189 · Phase 3 · registry result, not featured evidence
—800 μg
NCT02479412 · Phase 2 · registry result, not featured evidence
—250 μg
NCT02479412 · Phase 2 · registry result, not featured evidence
—58 μg
NCT02479412 · Phase 2 · registry result, not featured evidence
—100 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
—50 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
—25 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
—12.5 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
0%250 µg QD
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
0%125 µg QD
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
0%62.5 µg QD
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
—31.5 µg QD
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
0%31.25 µg BID
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
0%31.25 µg QD
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
0%15.6 µg BID
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
0%15.6 µg QD
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
—200 ug
NCT06433908 · Phase 1 · registry result, not featured evidence
—800 ug
NCT06433908 · Phase 1 · registry result, not featured evidence
0.7%100/31.25/25 mcgb
NCT02924688 · Phase 3 · combination · Asthma · phase 3
show 8 more results
0.7%200/31.25/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
0.5%100/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
0.5%200/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
0%FF 200 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3
0%FF 100 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3
2.1%100/62.5/25 mcg
NCT03184987 · Phase 3 · combination
0%100/62.5/25 mcg to 200/62.5/25 mcg
NCT03184987 · Phase 3 · combination
1.8%200/62.5/25 mcg
NCT03184987 · Phase 3 · combination
Serious AEs
3%100 mg SCa
NCT04276233 · Phase 4 · registry result, not featured evidence
show 38 more results
0%Exercising in Filtered Air Followi
NCT05087693 · Phase 4 · registry result, not featured evidence
0%Exercising in Ozone Following Salb
NCT05087693 · Phase 4 · registry result, not featured evidence
4.2%
NCT03924635 · Phase 4 · registry result, not featured evidence · combination
11%100 mg SC
NCT02654145 · Phase 4 · registry result, not featured evidence
2.3%
NCT01471340 · Phase 4 · registry result, not featured evidence · pooled
0.5%50/250 mcg
NCT00363480 · Phase 4 · registry result, not featured evidence
2.1%100/62.5/25 mcg
NCT03184987 · Phase 3 · registry result, not featured evidence
0%100/62.5/25 mcg to 200/62.5/25 mcg
NCT03184987 · Phase 3 · registry result, not featured evidence
3.6%200/62.5/25 mcg
NCT03184987 · Phase 3 · registry result, not featured evidence
1.1%100/10 mcg BID
NCT02741271 · Phase 3 · registry result, not featured evidence
0%
NCT02502734 · Phase 3 · registry result, not featured evidence
9.8%200/12.5 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
6.4%200 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
5%100/12.5 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
5.5%100 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
0.8%
NCT01687296 · Phase 3 · registry result, not featured evidence
3.4%200 µg OD
NCT01431950 · Phase 3 · registry result, not featured evidence
2.5%100 µg OD
NCT01431950 · Phase 3 · registry result, not featured evidence
0.6%160 µg
NCT00384189 · Phase 3 · registry result, not featured evidence
1.6%80 µg
NCT00384189 · Phase 3 · registry result, not featured evidence
1.3%40 µg
NCT00384189 · Phase 3 · registry result, not featured evidence
0%800 μg
NCT02479412 · Phase 2 · registry result, not featured evidence
0%250 μg
NCT02479412 · Phase 2 · registry result, not featured evidence
0%58 μg
NCT02479412 · Phase 2 · registry result, not featured evidence
1.9%100 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
1%50 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
0%25 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
0%12.5 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
0.7%250 µg QD
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
0%125 µg QD
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
0%62.5 µg QD
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
0%31.5 µg QD
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
0%31.25 µg BID
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
—31.25 µg QD
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
0%15.6 µg BID
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
0%15.6 µg QD
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
3.3%200 ug
NCT06433908 · Phase 1 · registry result, not featured evidence
0%800 ug
NCT06433908 · Phase 1 · registry result, not featured evidence
4.4%100/31.25/25 mcgb
NCT02924688 · Phase 3 · combination · Asthma · phase 3
show 8 more results
5.7%200/31.25/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
5.7%100/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
5.1%200/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
1.1%FF 200 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3
3.3%FF 100 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3
2.1%100/62.5/25 mcg
NCT03184987 · Phase 3 · combination
0%100/62.5/25 mcg to 200/62.5/25 mcg
NCT03184987 · Phase 3 · combination
3.6%200/62.5/25 mcg
NCT03184987 · Phase 3 · combination
Most frequent reported AEs
100 mg SCa
pyrexia 5%
headache 3%
oropharyngeal pain 3%
NCT04276233 · Phase 4 · registry result, not featured evidence
show 34 more results
100 mg SC
headache 28.3%
viral upper respiratory tract infection 16.6%
bronchitis 13.1%
NCT02654145 · Phase 4 · registry result, not featured evidence
asthma 0.1%
dry mouth 0.1%
dysphonia 0.1%
NCT01471340 · Phase 4 · registry result, not featured evidence · pooled
50/250 mcg
headache 10.4%
nasopharyngitis 8.1%
bronchitis 5.4%
NCT00363480 · Phase 4 · registry result, not featured evidence
100/62.5/25 mcg
nasopharyngitis 27.7%
pharyngitis 10.6%
bronchitis 8.5%
NCT03184987 · Phase 3 · registry result, not featured evidence
100/62.5/25 mcg to 200/62.5/25 mcg
bronchitis 22.2%
dysgeusia 22.2%
nasopharyngitis 22.2%
NCT03184987 · Phase 3 · registry result, not featured evidence
200/62.5/25 mcg
nasopharyngitis 32.7%
dysgeusia 10.9%
eczema 9.1%
NCT03184987 · Phase 3 · registry result, not featured evidence
100/10 mcg BID
asthma 11%
upper respiratory tract infection 9.9%
influenza 5.5%
NCT02741271 · Phase 3 · registry result, not featured evidence
nasopharyngitis 6.9% (placebo 8.3%)
headache 5.2% (placebo 13.3%)
cough 3.4% (placebo 5%)
NCT02502734 · Phase 3 · registry result, not featured evidence
200/12.5 mcg
upper respiratory tract infection 18%
sinusitis 10.5%
nasopharyngitis 9%
NCT02175771 · Phase 3 · registry result, not featured evidence
200 mcg
upper respiratory tract infection 13.6%
cough 10.4%
nasopharyngitis 10.4%
NCT02175771 · Phase 3 · registry result, not featured evidence
100/12.5 mcg
upper respiratory tract infection 17.5%
nasopharyngitis 12.5%
cough 11.7%
NCT02175771 · Phase 3 · registry result, not featured evidence
100 mcg
upper respiratory tract infection 18.1%
nasopharyngitis 13.4%
sinusitis 11.8%
NCT02175771 · Phase 3 · registry result, not featured evidence
white blood cell count increased 0.8%
NCT01687296 · Phase 3 · registry result, not featured evidence
200 µg OD
headache 12.6%
nasopharyngitis 12.6%
bronchitis 6.7%
NCT01431950 · Phase 3 · registry result, not featured evidence
100 µg OD
bronchitis 11.8%
nasopharyngitis 11.8%
headache 10.1%
NCT01431950 · Phase 3 · registry result, not featured evidence
160 µg
pharyngitis 5.2% (placebo 4.8%)
upper respiratory tract infection 5.2% (placebo 3.4%)
nasopharyngitis 4.2% (placebo 2.1%)
NCT00384189 · Phase 3 · registry result, not featured evidence
80 µg
upper respiratory tract infection 6.4% (placebo 3.4%)
pharyngitis 5.8% (placebo 4.8%)
nasopharyngitis 3.2% (placebo 2.1%)
NCT00384189 · Phase 3 · registry result, not featured evidence
40 µg
nasopharyngitis 6.2% (placebo 2.1%)
upper respiratory tract infection 5.9% (placebo 3.4%)
pharyngitis 4.6% (placebo 4.8%)
NCT00384189 · Phase 3 · registry result, not featured evidence
800 μg
nasopharyngitis 11.8% (placebo 15.4%)
diarrhoea 8.8% (placebo 0%)
headache 5.9% (placebo 0%)
NCT02479412 · Phase 2 · registry result, not featured evidence
250 μg
headache 8.8% (placebo 0%)
nasopharyngitis 5.9% (placebo 15.4%)
asthma 2.9% (placebo 1.9%)
NCT02479412 · Phase 2 · registry result, not featured evidence
58 μg
nasopharyngitis 11.8% (placebo 15.4%)
gastroenteritis 8.8% (placebo 0%)
cough 5.9% (placebo 1.9%)
NCT02479412 · Phase 2 · registry result, not featured evidence
100 mcg
upper respiratory tract infection 4.9% (placebo 2.9%)
nasopharyngitis 2.9% (placebo 4.8%)
NCT01479621 · Phase 2 · registry result, not featured evidence
50 mcg
nasopharyngitis 6.7% (placebo 4.8%)
upper respiratory tract infection 2.9% (placebo 2.9%)
NCT01479621 · Phase 2 · registry result, not featured evidence
25 mcg
nasopharyngitis 4.8% (placebo 4.8%)
upper respiratory tract infection 1.9% (placebo 2.9%)
NCT01479621 · Phase 2 · registry result, not featured evidence
12.5 mcg
upper respiratory tract infection 6.8% (placebo 2.9%)
nasopharyngitis 3.9% (placebo 4.8%)
NCT01479621 · Phase 2 · registry result, not featured evidence
250 µg QD
headache 4.4% (placebo 1.6%)
product taste abnormal 3.7% (placebo 0%)
nasopharyngitis 0.7% (placebo 0.8%)
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
125 µg QD
headache 3.1% (placebo 1.6%)
product taste abnormal 3.1% (placebo 0%)
nasopharyngitis 2.3% (placebo 0.8%)
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
62.5 µg QD
headache 3.8% (placebo 1.6%)
pharyngitis 3.8% (placebo 0.8%)
nasopharyngitis 0.8% (placebo 0.8%)
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
31.5 µg QD
headache 2.9% (placebo 1.6%)
product taste abnormal 1.4% (placebo 0%)
pharyngitis 0.7% (placebo 0.8%)
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
31.25 µg BID
headache 4.5% (placebo 1.6%)
nasopharyngitis 1.5% (placebo 0.8%)
pharyngitis 0% (placebo 0.8%)
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
15.6 µg BID
nasopharyngitis 3.2% (placebo 0.8%)
headache 1.6% (placebo 1.6%)
pharyngitis 0.8% (placebo 0.8%)
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
15.6 µg QD
headache 3.8% (placebo 1.6%)
nasopharyngitis 2.3% (placebo 0.8%)
pharyngitis 0% (placebo 0.8%)
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
200 ug
catheter site haematoma 16.7%
headache 10%
abdominal pain 6.7%
NCT06433908 · Phase 1 · registry result, not featured evidence
800 ug
catheter site related reaction 30%
headache 16.7%
cough 10%
NCT06433908 · Phase 1 · registry result, not featured evidence
100/31.25/25 mcgb
nasopharyngitis 13.8%
headache 7.7%
upper respiratory tract infection 5.9%
NCT02924688 · Phase 3 · combination · Asthma · phase 3
show 8 more results
200/31.25/25 mcg
nasopharyngitis 12.6%
headache 6.7%
bronchitis 4%
NCT02924688 · Phase 3 · combination · Asthma · phase 3
100/62.5/25 mcg
nasopharyngitis 14.8%
headache 8.9%
bronchitis 3.7%
NCT02924688 · Phase 3 · combination · Asthma · phase 3
200/62.5/25 mcg
nasopharyngitis 12.5%
bronchitis 5.4%
headache 4.7%
NCT02924688 · Phase 3 · combination · Asthma · phase 3
FF 200 ug, UMEC 62.5 ug, VI 25 ug
covid-19 5.7%
nasopharyngitis 4.5%
upper respiratory tract infection 4.5%
NCT04937387 · Phase 3 · Asthma · phase 3
FF 100 ug, UMEC 62.5 ug, VI 25 ug
upper respiratory tract infection 7.8%
covid-19 3.3%
nasopharyngitis 3.3%
NCT04937387 · Phase 3 · Asthma · phase 3
100/62.5/25 mcg
nasopharyngitis 27.7%
pharyngitis 10.6%
bronchitis 8.5%
NCT03184987 · Phase 3 · combination
100/62.5/25 mcg to 200/62.5/25 mcg
bronchitis 22.2%
dysgeusia 22.2%
nasopharyngitis 22.2%
NCT03184987 · Phase 3 · combination
200/62.5/25 mcg
nasopharyngitis 32.7%
dysgeusia 10.9%
eczema 9.1%
NCT03184987 · Phase 3 · combination

Notes

  1. aPopulation comparability has not been reviewed for 31 of these studies.
  2. bPopulation comparability has not been reviewed for 3 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

albuterol (Ventolin)

Asthma Exacerbation Occurrence 8% (n=100) @ 24wk100 mg SC
event count · % of participants
No placebo or comparator arm
NCT04276233 · Phase 4 · registry result, not featured evidence · converted to % from 8 Participants as posted
Asthma Exacerbation Hospitalization Occurrence 2% (n=100) @ 24wk100 mg SC
event count · % of participants
No placebo or comparator arm
NCT04276233 · Phase 4 · registry result, not featured evidence · converted to % from 2 Participants as posted
show 1 more result
2% (n=100) @ 24wk*100 mg SC
NCT04276233 · Phase 4 · registry result, not featured evidence · converted to % from 2 Participants as posted
FEV1 0.284 L @ 24wk200 µg OD
absolute change · L
No placebo or comparator arm
NCT01431950 · Phase 3 · registry result, not featured evidence
show 6 more results
0.081 L @ 24wk100 mg SC
NCT04276233 · Phase 4 · registry result, not featured evidence
0.055 L @ 24wk100 mg SC
NCT04276233 · Phase 4 · registry result, not featured evidence
0.208 L @ 24wk100 µg OD
NCT01431950 · Phase 3 · registry result, not featured evidence
0.133 L @ 4wk50/250 mcg
NCT00363480 · Phase 4 · registry result, not featured evidence
0.212 L @ 8wk50/250 mcg
NCT00363480 · Phase 4 · registry result, not featured evidence
0.181 L @ 12wk50/250 mcg
NCT00363480 · Phase 4 · registry result, not featured evidence
ACQ-5 -0.69 score @ 24wk100 mg SC
absolute change · score
No placebo or comparator arm
NCT04276233 · Phase 4 · registry result, not featured evidence
show 1 more result
-1.45 score @ 32wk100 mg SC
NCT02654145 · Phase 4 · registry result, not featured evidence
Morning PEF Change L/Min 13.67 L/min @ 24wk100 mg SC
absolute change · L/min
No placebo or comparator arm
NCT04276233 · Phase 4 · registry result, not featured evidence
FEV1 0.139 vs 0.039 placebo L @ 12wk160 µg
absolute change · L
NCT00384189 · Phase 3 · registry result, not featured evidence
show 4 more results
0.122 vs 0.039 placebo L @ 12wk80 µg
NCT00384189 · Phase 3 · registry result, not featured evidence
0.123 vs 0.039 placebo L @ 12wk40 µg
NCT00384189 · Phase 3 · registry result, not featured evidence
6.98 vs -1.38 placebo L
NCT05087693 · Phase 4 · registry result, not featured evidence
5.96 vs -1.38 placebo L
NCT05087693 · Phase 4 · registry result, not featured evidence
FVC Change 0.77 vs -1.37 placebo L
absolute change · L
NCT05087693 · Phase 4 · registry result, not featured evidence
show 1 more result
0.39 vs -1.37 placebo L
NCT05087693 · Phase 4 · registry result, not featured evidence
Exhaled no Change Ppb 9.01 parts per billion (ppb) @ 24wk
absolute change · parts per billion (ppb)
No placebo or comparator arm
NCT03924635 · Phase 4 · registry result, not featured evidence · combination
Asthma Symptom -0.59 score @ 12wk50/250 mcg
absolute change · score
No placebo or comparator arm
NCT00363480 · Phase 4 · registry result, not featured evidence
show 1 more result
0.83 score @ 24wk
NCT03924635 · Phase 4 · registry result, not featured evidence · combination
Rescue Medication Use -0.933 count @ 12wk50/250 mcg
absolute change · count
No placebo or comparator arm
NCT00363480 · Phase 4 · registry result, not featured evidence
show 1 more result
1.16 count @ 24wk
NCT03924635 · Phase 4 · registry result, not featured evidence · combination
SGRQ Total -19 score @ 32wk100 mg SC
absolute change · score
No placebo or comparator arm
NCT02654145 · Phase 4 · registry result, not featured evidence
Severe Exacerbation Rate Annualized 1.18 per year @ 32wk100 mg SC
event rate · per year
No placebo or comparator arm
NCT02654145 · Phase 4 · registry result, not featured evidence

+ 40 further endpoints in the CSV export.

fluticasone furoate/umeclidinium/vilanterol

FEV1 Change 3 h 0.22 vs 0.132 FF/VI L @ 24wk100/31.25/25 mcg
absolute change · L
NCT02924688 · Phase 3 · combination · Asthma · phase 3
show 3 more results
0.256 vs 0.132 FF/VI L @ 24wk200/31.25/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
0.243 vs 0.132 FF/VI L @ 24wk100/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
0.286 vs 0.132 FF/VI L @ 24wk200/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
ACQ-7 -0.814 vs -0.94 Fluticasone Furoate [FF] / Vilanterol [VI] score @ 12wkFF 200 ug, UMEC 62.5 ug, VI 25 ug
absolute change · score
NCT04937387 · Phase 3 · Asthma · phase 3
show 1 more result
-0.968 vs -0.94 Fluticasone Furoate [FF] / Vilanterol [VI] score @ 12wkFF 100 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: albuterol (Ventolin)'s landscape · fluticasone furoate/umeclidinium/vilanterol's landscape